3/11
10:18 am
alny
Rating for ALNY
Low
Report
Rating for ALNY
2/26
12:25 pm
alny
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at William Blair.
Low
Report
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at William Blair.
2/26
12:25 pm
alny
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at William Blair.
Low
Report
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at William Blair.
2/26
11:36 am
alny
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $310.00 price target on the stock.
Low
Report
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $310.00 price target on the stock.
2/26
11:36 am
alny
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $310.00 price target on the stock.
Low
Report
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $310.00 price target on the stock.
2/26
11:34 am
alny
Rating for ALNY
Low
Report
Rating for ALNY
2/26
11:34 am
alny
Rating for ALNY
Low
Report
Rating for ALNY
2/26
08:15 am
alny
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $300.00 price target on the stock.
Low
Report
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $300.00 price target on the stock.
2/26
08:06 am
alny
Rating for ALNY
Low
Report
Rating for ALNY
2/26
08:00 am
alny
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $320.00 price target on the stock.
Low
Report
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $320.00 price target on the stock.
2/26
07:23 am
alny
Rating for ALNY
Low
Report
Rating for ALNY
2/26
07:23 am
alny
Rating for ALNY
Low
Report
Rating for ALNY
2/18
06:47 am
alny
Rating for ALNY
Low
Report
Rating for ALNY
2/14
12:46 pm
alny
Rating for ALNY
Low
Report
Rating for ALNY
2/14
12:46 pm
alny
Rating for ALNY
Low
Report
Rating for ALNY
2/14
09:00 am
alny
Rating for ALNY
Medium
Report
Rating for ALNY
2/14
09:00 am
alny
Rating for ALNY
Medium
Report
Rating for ALNY
2/14
08:07 am
alny
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $320.00 price target on the stock.
Medium
Report
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $320.00 price target on the stock.
2/14
05:56 am
alny
Rating for ALNY
Medium
Report
Rating for ALNY
2/14
05:56 am
alny
Rating for ALNY
Medium
Report
Rating for ALNY
2/11
12:29 pm
alny
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $300.00 price target on the stock.
Low
Report
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $300.00 price target on the stock.
2/11
12:29 pm
alny
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $300.00 price target on the stock.
Low
Report
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $300.00 price target on the stock.
2/11
11:58 am
alny
Rating for ALNY
Low
Report
Rating for ALNY
2/11
11:58 am
alny
Rating for ALNY
Low
Report
Rating for ALNY
1/21
12:19 pm
alny
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $300.00 price target on the stock.
Low
Report
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $300.00 price target on the stock.